Dr. Reddy's Laboratories (RDY) News
NYSE: RDYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.89+0.06 (+0.40%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RDY news summary
We found 44 recent headlines mentioning Dr. Reddy's Laboratories (RDY): 1 in the past week and 13 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, RDY is up 0.40% at $14.89. The most recent story, "Dr. Reddy's Laboratories Limited Announces USFDA Closes Inspection at FTO-3 Facility", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Dr. Reddy's Laboratories headlines
- Dr. Reddy's Laboratories Limited Announces USFDA Closes Inspection at FTO-3 FacilityDr. Reddy's Laboratories Limited has announced that the United States Food & Drug Administration (USFDA) has classified the inspection outcome at its formulations manufacturing facility (FTO-3) in…NasdaqRDY, LEN.B
- Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split(RTTNews) - The healthcare sector saw a busy week, with several companies securing regulatory approvals, announcing workforce restructuring, and advancing strategic business deals.NasdaqABT, AGIO, BEAT, BIOA
- Dr. Reddy's Laboratories Limited Receives Marketing Authorization for Generic Semaglutide Injection in BrazilDr. Reddy’s Laboratories Limited announced that Brazil’s National Health Surveillance Agency (ANVISA) has granted marketing authorization for generic semaglutide injection for the…Nasdaq
- Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative(RTTNews) - Dr.Reddy's Laboratories (RDY) has received marketing authorization from Brazil's health regulator, ANVISA, for its generic semaglutide injection, expanding the company's presence in one…NasdaqRDY, BRK.A
- Dr. Reddy's Laboratories Limited Allots 5,91,270 Equity Shares Under Employees ADR Stock Options Scheme, 2007Dr. Reddy's Laboratories Limited has allotted 5,91,270 equity shares of Re.1/- each of the Company, fully paid up, on November 4, 2026, to eligible employees pursuant to exercise of their Stock…Nasdaq
- Reddy's Gets Tentative FDA Nod For Twice-Yearly HIV Prevention Shot At $40 A Year(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) said Monday the U.S. Food and Drug Administration granted tentative approval to its twice-yearly injectable lenacapavir for HIV prevention under the…Nasdaq
- Dr. Reddy's Laboratories Limited Announces USFDA Classifies FTO-SEZ Process Unit-02 Inspection as Voluntary Action IndicatedOn October 28, 2026, Dr. Reddy's Laboratories Limited announced that the United States Food & Drug Administration has classified the inspection outcome for its FTO-SEZ Process Unit-02, Srikakulam,…Nasdaq
- RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallDr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.NasdaqRDY, HALO, TGTX, HRMY
- Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term InvestorsKey PointsSemaglutide supply reloading will begin by November 2026.NasdaqRDY, WSO.B
- Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call TranscriptSeeking Alpha
- Dr. Reddy's Laboratories Limited Reports Q2 FY 2027 Financial ResultsDr. Reddy's Laboratories Limited announced its consolidated financial results for the quarter ended September 30, 2026. The company reported revenues of ₹ 86,708 Mn, representing a decline of…Nasdaq
- Dr. Reddy's Laboratories Limited Appoints Akhil Ravi as Head API and Services Effective November 13, 2026Dr. Reddy's Laboratories Limited announced that its Board of Directors approved the appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel of the Company, and his…Nasdaq
- Dr. Reddy's Laboratories Q2 Earnings Call HighlightsTeva Pharmaceuticals Stock: Unlock Value in This Generic Drug GemDr. Reddy's Laboratories (NYSE:RDY) reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year…Nasdaq
- Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqRDY, HEI.A
- Dr. Reddy's Laboratories Limited 2027 Q2 - Results - Earnings Call PresentationSeeking Alpha
- Dr. Reddy's Laboratories Limited Reports Revenues of Rs. 86,708 Million for the Quarter Ended September 30, 2026Dr. Reddy's Laboratories Limited reported revenues of Rs. 86,708 million for the three months ended September 30, 2026, representing a decrease of 2% compared to Rs. 88,051 million for the three…Nasdaq
- Dr. Reddy's Laboratories Profit Drops In Q2(RTTNews) - Friday, Dr. Reddy's Laboratories Limited (RDY) announced its financial results for the second quarter of fiscal 2027.Nasdaq
- RDY Crosses Above Key Moving Average LevelIn trading on Tuesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $13.21, changing hands as high as $13.35 per share. Dr. Reddy's Laboratories…Nasdaq
- Top Stock Reports for Oracle, American Express & ProgressiveOracle, American Express and Progressive face contrasting challenges and growth drivers, from underperformance to rising expenses, premium growth and strategic investments.NasdaqAXP, ORCL, PGR, RDY
- Highest and lowest quant-rated healthcare stocks above $10B cap after earnings seasonSeeking Alpha
- NBIX vs. TEVA: Which Drugmaker Is the Better Investment?Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.NasdaqTEVA, NBIX, RDY, LLY
- Dr. Reddy's Launches First-to-Market Generic Sugammadex Injection In The U.S(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced the U.S. launch of its Sugammadex Injection in single-dose vials of 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), marking the first…Nasdaq
- Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock DownRDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.NasdaqRDY, NBIX, AMRN, LQDA
- Dr. Reddy's Laboratories Q1 Net Profit Drops As Revenue Slips, Expenses Climb(RTTNews) - Dr. Reddy's Laboratories Limited (RDY, 500124, DRREDDY), a major Indian pharmaceutical company, on Thursday posted a decline in net income for the first quarter, hurt by decreased revenue…Nasdaq
- Dr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call TranscriptSeeking Alpha
- Dr. Reddy's Laboratories Enters Oversold Territory (RDY)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…Nasdaq
- Dr. Reddy's Laboratories Q1 Earnings Call HighlightsTeva Pharmaceuticals Stock: Unlock Value in This Generic Drug GemDr. Reddy's Laboratories (NYSE:RDY) reported a year-over-year revenue decline and sharply lower profitability for the first quarter of…Nasdaq
- Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall RiskTeva Pharmaceuticals Stock: Unlock Value in This Generic Drug GemDr. Reddy's Laboratories (NYSE:RDY) said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection…Nasdaq
- Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide TranscriptSeeking Alpha
- Monday's ETF Movers: BUG, EMEQIn trading on Monday, the Global X Cybersecurity ETF is outperforming other ETFs, up about 3.9% on the day. Components of that ETF showing particular strength include shares of Gorilla Technology…NasdaqGRRR, PANW, RDY, TKC
- Bullish Two Hundred Day Moving Average Cross - RDYIn trading on Monday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $13.85, changing hands as high as $14.03 per share. Dr. Reddy's Laboratories…Nasdaq
- Dr. Reddy's Laboratories Q4 Earnings Call HighlightsTeva Pharmaceuticals Stock: Unlock Value in This Generic Drug GemDr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026…Nasdaq
- Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock DownRDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.NasdaqRDY, BMY, NVO, AMRN
- Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call TranscriptSeeking Alpha
- AMPH vs. RDY: Which Stock Should Value Investors Buy Now?AMPH vs. RDY: Which Stock Is the Better Value Option?NasdaqAMPH, RDY
- AMRX Valuation: What 1.69x Sales Means for InvestorsAmneal trades at 1.69x sales, below sector benchmarks, as investors weigh raised 2026 profit guidance against Specialty pressure and launch execution.NasdaqRDY, TEVA, AMRX
- ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock DownEsperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.NasdaqRDY, ANIP
- Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call TranscriptSeeking Alpha
- Dr. Reddy's: Underappreciated Future Amid Exaggerated HeadwindsSeeking Alpha
- Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Dr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New RevenuesSeeking Alpha
- Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call TranscriptSeeking Alpha
- Dr. Reddy's Laboratories Limited 2026 Q1 - Results - Earnings Call PresentationSeeking Alpha
- Dr. Reddy's Continues To Be A Good Buy At Current ValuationSeeking Alpha